The agreement allows the companies to support for the planned clinical trials of a cancer drug – Kevetrin.
Cellceutix develops drugs to treat preclinical cancer, anti-inflammatory and autism.
Cellceutix other drug include KM-391to treat autism and KM-133 to treat psoriasis.